DICE Therapeutics Inc (DICE) Stock Price & Overview
NASDAQ:DICE • US23345J1043
Current stock price
The current stock price of DICE is 47.55 USD. Today DICE is up by 0.06%. In the past month the price increased by 1.67%. In the past year, price increased by 136.1%.
DICE Key Statistics
- Market Cap
- 2.272B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.18
- Dividend Yield
- N/A
DICE Stock Performance
DICE Stock Chart
DICE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DICE. When comparing the yearly performance of all stocks, DICE is one of the better performing stocks in the market, outperforming 98.59% of all stocks.
DICE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DICE. While DICE has a great health rating, there are worries on its profitability.
DICE Earnings
DICE Forecast & Estimates
14 analysts have analysed DICE and the average price target is 50.36 USD. This implies a price increase of 5.91% is expected in the next year compared to the current price of 47.55.
DICE Groups
Sector & Classification
DICE Financial Highlights
Over the last trailing twelve months DICE reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS decreased by -20.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DICE Ownership
DICE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.48 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.67 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.838B | ||
| PFE | PFIZER INC | 9.32 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.36 | 121.374B | ||
| ZTS | ZOETIS INC | 16.68 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.16 | 28.018B | ||
| VTRS | VIATRIS INC | 5.35 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.69 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.49 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DICE
Company Profile
DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing oral therapeutics against well-validated targets in immunology. The firm's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The firm's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
Company Info
IPO: 2021-09-15
DICE Therapeutics Inc
400 East Jamie Court, Suite 300
South San Francisco CALIFORNIA US
CEO: J. Kevin Judice
Employees: 81
Phone: 16505661402.0
DICE Therapeutics Inc / DICE FAQ
Can you describe the business of DICE Therapeutics Inc?
DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing oral therapeutics against well-validated targets in immunology. The firm's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The firm's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
What is the current price of DICE stock?
The current stock price of DICE is 47.55 USD. The price increased by 0.06% in the last trading session.
Does DICE Therapeutics Inc pay dividends?
DICE does not pay a dividend.
What is the ChartMill technical and fundamental rating of DICE stock?
DICE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists DICE stock?
DICE stock is listed on the Nasdaq exchange.
Can you provide the market cap for DICE Therapeutics Inc?
DICE Therapeutics Inc (DICE) has a market capitalization of 2.27B USD. This makes DICE a Mid Cap stock.